New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2013
13:09 EDTNAVB, CAHFDA approves Navidea Lymphoseek injection for use in lymphatic mapping
Navidea Biopharmaceuticals (NAVB) announced U.S. Food and Drug Administration approval of Lymphoseek Injection, a novel product indicated for use in lymphatic mapping procedures to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma. Lymphoseek will be sold and distributed in the U.S. on an exclusive basis by Cardinal Health (CAH).
News For NAVB;CAH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
07:38 EDTNAVBNavidea announces presentation of Lymphoseek studies results
Subscribe for More Information
07:03 EDTCAHCardinal Health reports Q1 EPS $1.00, consensus 96c
Subscribe for More Information
October 29, 2014
15:41 EDTCAHNotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use